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Abstract
Background: Antiretroviral prophylaxis may be a critical strategy to reduce periconception HIV transmission. Maximizing the
benefit of periconception pharmacologic HIV risk-reduction requires an understanding of the links between pregnancy and
adherence to this prevention strategy.
Methods: We assessed study gel adherence among women with pregnancies compared to women without pregnancies
enrolled in the CAPRISA 004 phase IIB trial of 1% vaginal tenofovir gel. Pregnancy was assessed with monthly urine tests.
Adherence was measured monthly and defined as proportion of sex acts covered by two returned, used applicators based
on pre- and post-coital dosing. High adherence was defined as a median adherence score of .80%, that is, more than 80%
of sex acts were covered by two applications of study gel. A multivariate generalized estimating equations (GEE) model with
a binomial distribution was used to assess covariates associated with high adherence (.80%) over time. Median adherence
before and after pregnancy was compared using Wilcoxon signed rank test.
Results: Among 868 women, 53 had at least 1 pregnancy (4.06 per 100 woman years, 95% CI: 3.04, 5.31). Women with
pregnancies had lower median adherence compared to women without pregnancies (50% [IQR: 45–83] vs. 60% [IQR: 50–
100], p=0.02). Women with pregnancies also had a 48% lower odds of high adherence compared to women without
pregnancies when adjusting for confounders (aOR 0.52, 95%CI: 0.41–0.66, p,0.0001). Among women with pregnancies,
adherence before and after pregnancy was not different (50% [IQR: 46–83] vs. 55% [IQR: 20–100], p=0.68).
Conclusions: Women with pregnancies were less likely to have high adherence to study gel compared to women without
pregnancies. Understanding these differences may inform findings from HIV prevention trials and future implementation of
antiretroviral prophylaxis for at-risk women who choose to conceive. The protocol for the parent trial is registered on
ClinicalTrials.gov, NCT00441298, http://www.clinicaltrials.gov/ct2/show/NCT00441298.
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Introduction
In sub-Saharan Africa, the majority of new HIV infections
occur in women of childbearing age [1]. Antenatal clinic surveys in
KwaZulu-Natal, South Africa demonstrate HIV prevalence as
high as 46% [2]. While many pregnancies are not planned [3,4],
young women may desire pregnancy to meet her own re-
productive goals, cement a relationship with a partner, prove
her womanhood and suitability as a future wife, or demonstrate
health in an era of HIV-related infertility [5,6,7,8,9,10,11,12].
Becoming pregnant is risky in settings with high HIV prevalence
as current prevention strategies, condoms and abstinence, do not
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e56400allow for conception. In addition, pregnancy is associated with
increased risks of HIV acquisition and transmission [13,14,15].
HIV-uninfected women who desire pregnancy with a partner who
is HIV-infected or at high risk of being infected require protective
strategies for themselves and their future children [16].
Reproductive technologies to reduce periconception HIV
transmission risk, including sperm processing, are inaccessible to
most [17,18]. Behavioral strategies such as home manual
insemination and unprotected sex limited to peak fertility, and
medical strategies including male circumcision [19,20,21] and
suppressive antiretrovirals (ARVs) for the positive partner [22] are
potential elements of periconception HIV risk reduction for
serodiscordant couples [23,24,25,26]. Topical or systemic anti-
retroviral pre-exposure prophylaxis (PrEP) may also be a critical
component of strategies to reduce periconception HIV trans-
mission for HIV discordant couples who choose to conceive,
particularly if a positive partner does not qualify for or want to
take suppressive ARVs [27,28,29,30].
In the first proof of concept microbicide trial, HIV acquisition
rates among women using 1% tenofovir vaginal gel were reduced
by 39% [31]. HIV acquisition rates were reduced by 44% among
HIV-seronegative men or transgender women having sex with
men and taking tenofovir/emtricitabine in iPrEX [32]; by 67%
and 75% among uninfected partners in HIV-serodiscordant
couples taking tenofovir or tenofovir/emtricitabine, respectively,
in the Partners PrEP trial [33]; and by 63% among uninfected
men and women taking tenofovir/emtricitabine in the CDC
TDF2 trial [34]. Conversely, the FEM-PrEP trial of oral daily
tenofovir/emtricitabine and the VOICE trial arms of oral and
vaginal tenofovir for heterosexual women were halted for futility
[35,36,37].
Data from these trials suggest that topical or systemic PrEP will
work best for those who maintain high medication adherence
[31,32,33,35,38]. Women and couples desiring children may
represent a motivated, high-risk population who may benefit from
shorter-term PrEP to reduce sexual transmission while allowing for
conception [27,28,29]. Due to a relative lack of safety data for
tenofovir during pregnancy, trials including tenofovir as PrEP in
oral or topical formulations have excluded women with plans for
pregnancy. Despite extensive counseling and promotion (and, in
some cases, provision) of contraceptives, some women in these
trials become pregnant [35,39,40,41]. In the Partners PrEP Study
of daily oral tenofovir or tenofovir/emtricitabine as PrEP,
qualitative interviews with a subset of couples who became
pregnant while enrolled suggest a high proportion of intended
pregnancies [42]. Examining adherence to ARVs as prevention in
PrEP or microbicide trials provides an imperfect but early
opportunity to assess potential barriers to periconception phar-
macologic risk reduction strategies.
We evaluated pre-pregnancy adherence to study gel among
women with pregnancies enrolled in the Centre for the AIDS
Programme of Research in South Africa (CAPRISA)- 004 phase
Figure 1. Screening, enrollment, and pregnancy events in the CAPRISA 004 vaginal tenofovir gel trial.
doi:10.1371/journal.pone.0056400.g001
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conducted to assess safety and efficacy of 1% vaginal tenofovir gel
to reduce HIV acquisition in women [31]. We hypothesized that
women with pregnancies would have higher adherence to study
gel compared to women without pregnancies, in the setting of
greater perceived risk of HIV acquisition.
Methods
Ethics and Regulatory oversight
The CAPRISA 004 trial (NCT00441298) was approved by the
University of KwaZulu-Natal’s Biomedical Research Ethics
Committee (E111/06) and Family Health International’s Pro-
tection of Human Subjects Committee (#9946). Regulatory
oversight was provided by the South African Medicine Control
Council (#20060835).
Study design, population and setting
CAPRISA 004 was a phase IIb placebo-controlled, double-
blind randomized clinical trial conducted to assess safety and
efficacy of 1% vaginal tenofovir gel to reduce HIV acquisition in
women at one rural and one urban clinic in South Africa [31]. 889
non-pregnant HIV-uninfected women between the ages of 18 and
40 years were enrolled over 19 months (May 2007 through
January 2009) and followed for a mean of 18 months (range: 12
to 30 months). Participants were randomized to receive 1%
tenofovir or placebo gel and were instructed to use the gel up to
12 hours before sex, and within 12 hours after sex, without using
more than two gels in a 24 hour period. The protocol for this trial
is available as supporting information: see Protocol S1. Inclusion
criteria included negative response to ‘‘Do you have any plans to
become pregnant in the next three years?’’ and agreeing to use
a non-barrier method of contraception for the duration of the
study. For this analysis, we excluded 21 women who reported
a history of hysterectomy or tubal ligation at baseline (Figure 1).
Table 1. Baseline characteristics of study participants.
Baseline characteristics All subjects{ n=868 No Pregnancy n=815 Pregnancy n=53 p-value*
Age (years), median (IQR) 22 (20–26) 23 (19–27) 22 (20–26) 0.89
Site, n (%) 0.45
Rural 597 (68.8) 563 (69.1) 34 (64.2)
Urban 271 (31.2) 252 (30.9) 19 (35.8)
Live with regular partner, n (%) 0.70
Yes 98 (11.3) 94 (11.5) 4 (7.6)
No 762 (87.8) 713 (87.5) 49 (92.5)
No regular partner 8 (0.9) 8 (1.0) 0
Education, n (%) 1.00
Completed high-school and above 506 (58.3) 340 (41.7) 22 (41.5)
Did not complete high-school 362 (41.7) 475 (58.3) 31 (58.5)
1u Partner type, n (%) 0.34
Married 43 (5.0) 42 (5.2) 1 (1.9)
Stable
f 772 (88.9) 721 (88.5) 51 (96.2)
Other 53 (6.1) 52 (6.4) 1 (1.9)
Monthly income, n (%) 0.44
,145 USD 796 (91.7) 749 (91.9) 47 (88.7)
$145 USD 72 (8.3) 66 (8.1) 6 (11.3)
Living children, n (%) 0.26
0 197 (22.7) 180 (22.1) 17 (32.1)
1 470 (54.1) 445 (54.6) 25 (47.2)
$2 201 (23.2) 190 (23.3) 11 (20.8)
# Sex acts past 30 days, median (IQR) 6 (4–10) 6 (4–10) 6 (3–10) 0.69
Condom use past 30 days, n (%) 0.53
Always 255 (29.4) 242 (29.7) 13 (24.5)
Inconsistent 613 (70.6) 573 (70.3) 40 (75.5)
Contraception, n (%) ,0.001
Injectable 730 (84.1) 715 (87.7) 15 (28.3)
Oral 138 (15.9) 100 (12.3) 38 (71.1)
{Excluding women reporting prior tubal ligation or hysterectomy.
*Fisher’s exact test for categorical data and Wilcoxon two-sample test for continuous data.
fDefined to participants as ‘‘someone who you have a regular relationship with.’’
IQR: interquartile range.
doi:10.1371/journal.pone.0056400.t001
Pregnancy and Adherence in CAPRISA-004
PLOS ONE | www.plosone.org 3 March 2013 | Volume 8 | Issue 3 | e56400Pregnancy
Urine pregnancy tests (QuickVue One-Step hCG Urine Test
Quidel Corporation, San Diego, USA) were conducted at
screening, enrollment (if $21 days since screening), and monthly
follow-up visits. Pregnant women were excluded from enrollment.
Enrolled women who subsequently tested positive for pregnancy
continued follow-up visits but study product was temporarily held.
Study product resumed following a live birth or once ß-hcg levels
in serum or urine reverted to negative.
Contraception
Hormonal contraceptives were provided on-site at no cost,
including progesterone-containing injectables (depot-medroxypro-
gesterone acetate and norethisterone enanthate) and combined
oral contraceptives. Male and female condoms were promoted as
an HIV risk-reduction method and were provided at each study
visit.
Adherence
Participants were requested to return all used and unused
applicators from the preceding month at each follow-up visit. The
number of vaginal sex acts each month was recorded via face-to-
face structured interviews. Adherence was calculated by dividing
half the number of returned used applicators for each month by
the number of reported sex acts for that month. The median of
each participant’s monthly adherence estimates was assigned as
her overall gel adherence score. If a participant reported having no
sex in the month, an adherence score was not calculated for that
month. High adherence was defined as a median adherence score
of .80%, meaning a median of more than 80% of sex acts were
covered by two applications of study gel.
Statistical analysis
In this sub-study, we compared adherence prior to pregnancy
among study participants with pregnancies (n=53) to adherence
among study participants without pregnancies (n=815). Among
women with pregnancies who resumed product post-partum
(n=38), we assessed adherence prior to pregnancy and post-
partum.
Baseline characteristics of women with and without pregnancies
were compared using Fisher’s exact test for categorical data and
Wilcoxon two-sample test for continuous data. Wilcoxon signed
rank test was used to compare median adherence prior to
pregnancy and post-partum as well as 0–3 months prior to
pregnancy (periconception) and at least 4 months prior to
pregnancy (prior to conception). A multivariate generalized
estimating equations (GEE) model with a binomial distribution
was used to assess covariates associated with high adherence
(.80%) over time. Model covariates were selected based on a priori
knowledge and from unpublished data on predictors of high gel
adherence in this trial. Statistical analyses were carried out using
SAS (version 9.2; SAS Institute Inc., Cary, NC, USA). All
statistical tests were two-sided with type 1 error rate set to 0.05.
Results
Baseline characteristics
A total of 868 women were included in this analysis, median age
was 22 years (IQR: 20–26), 69% were from the rural study site,
58% had completed high school or above, and 89% reported
a stable sexual partner. Participants reported a median of 6 sex
acts in the past 30 days (IQR: 4–10), 29% reported always using
condoms in past 30 days. Twenty-three percent reported no living
children, 54% reported one, and 23% reported at least two living
children at enrollment. (Table 1).
At enrollment 730 women (84%) chose injectable hormonal
contraceptives and 138 (16%) chose oral contraceptives. Women
on oral contraceptives at baseline were slightly older (24 (IQR: 20–
29) vs. 22 (IQR: 20–26) years, p=0.01), more likely to have
completed high school (56% vs. 39% p=0.001), more likely to
have no living children (40% vs. 20%, p,0.0001), and more likely
to report monthly household income greater than 1001 South
African Rand (,145 USD) (13% vs. 7%, p=0.04) compared to
women on injectable contraception.
Pregnancy events
Fifty-three out of 868 women had 54 pregnancies over
30 months (4.06 per 100 woman years of follow-up, 95% CI:
3.04, 5.31) resulting in 35 full-term live births (one set of twins), 4
pre-term deliveries, 10 elective abortions, and 6 miscarriages [41].
Baseline characteristics including age, education, income, number
of live births, partner type, condom use, and number of sex acts in
past 30 days did not significantly differ between women with and
without pregnancies. Women with pregnancies were more likely to
be on oral contraception compared to women without pregnancies
(71% versus 12%, p,0.0001), as previously reported [41].
(Table 1).
Association between pregnancy events and adherence
to study product
Women with pregnancies (n=53) were less adherent to study
product with median adherence of 50% (IQR 46–83%) compared
to women without pregnancies (n=815) with median adherence of
60% (IQR 50–100%) (p=0.02). In unadjusted analysis, women
with pregnancy had a 42% lower odds of high adherence
compared to women without pregnancy (OR 0.58, 95% CI
0.46–0.73, p,.0001). In a multivariate model adjusting for
confounders of adherence and pregnancy, women with pregnancy
remained less likely to have high adherence to study product
(Adjusted OR 0.52, 95%CI: 0.41–0.66; p,0.0001). Contraceptive
choice was not associated with adherence to study product
(Table 2).
Adherence before and after pregnancy among those
with pregnancy events
Among women with pregnancies who resumed product post-
partum (n=38), median adherence to study drug prior to
pregnancy was 50% (IQR 46–83%) compared with 56% (IQR
20–100%) after resumption of study product (p=0.68). Among
women with pregnancies who had adherence data 0–3 months
prior to pregnancy (periconception) and $4 months prior to
pregnancy (n=30), adherence was 56% (IQR: 50–100%) 0–
3 months prior to pregnancy compared with 52% (IQR: 50–83%)
$4 months prior to pregnancy (p=0.07).
Discussion
In this analysis of prospective data from a randomized
controlled trial of 1% vaginal tenofovir gel as pre-exposure
prophylaxis for HIV prevention in South Africa, women with
pregnancies were less adherent to study product than women
without pregnancies. When adjusting for available confounders,
women with pregnancies had a 48% lower odds of high adherence
(two applications of gel with more than 80% of sex acts) to study
product prior to pregnancy diagnosis compared to women without
pregnancy.
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product in response to counseling messages. Tenofovir is an FDA
class B product [‘‘Adequate, well-controlled studies in pregnant
women have not shown an increased risk of fetal abnormalities
despite adverse findings in animals, or, in the absence of adequate
human studies, animal studies show no fetal risk. The chance of
fetal harm is remote, but remains a possibility’’ [43]] and study
participants were counseled about potential risks and taken off
study product in the event of pregnancy. This explanation
presumes intended pregnancy and informed avoidance of study
product. We do not have pregnancy intention data, however, there
was no significant difference between adherence prior to
pregnancy and post-partum in the subgroup of women with
pregnancies, or in periconception (0–3 months prior to pregnancy)
adherence compared to timepoints prior to conception
(.4 months prior to pregnancy). This may reflect a lack of power
to detect differences or suggest that women did not alter gel use in
the setting of planning pregnancy.
Women with pregnancies may have been less adherent to both
study product and contraception. This may reflect women who
enrolled in the study for secondary benefits but without particular
interest in the study product, or women who were simply not able
to adhere to study product or contraception. The only noted
difference between women with and without pregnancies at
enrollment was contraceptive choice. We do not have contracep-
tion adherence data but women on oral contraception – which
requires daily adherence – were more likely to become pregnant
than women on injectables. Interestingly, women on oral contra-
ceptives were slightly older and more likely to have completed high
school, have no children, and report monthly household income
greater than 145 USD than women on injectable contraception.
These women may have been prepared to have children and may
have chosen a contraceptive method which they could readily
control. If choice of oral contraception marked pregnancy desire,
this choice did not impact adherence to study gel in the model,
again suggesting that women did not avoid study product in the
setting of planning pregnancy. In addition, while some women
switched contraceptive methods during the study, only two women
with pregnancies switched from injectables to oral contraceptives
prior to her pregnancy. Of note, among the three women with
pregnancies who acquired HIV, all were in the placebo arm [41].
Additional details regarding contraceptive use, HIV seroconver-
sion, and pregnancy have been published [41]. A manuscript on
the predictors of adherence (besides pregnancy) in this study is in
preparation.
These data address two points for future prevention trials. The
rate of pregnancy in this study (4.06 per 100 woman years of
follow-up, 95% CI: 3.04, 5.31) is lower than that observed in other
HIV prevention trials [39,40,44,45,46,47,48] but illustrates that
some women who do not plan pregnancy and have excellent
access to contraception become pregnant. Prevention studies must
anticipate pregnancies and incorporate analyses to understand the
nature of the pregnancy (e.g. intention, partner role in decision),
adherence to study drug, and pregnancy outcomes in order to
understand efficacy and safety. In this study, choice of or switch to
oral contraception was associated with pregnancy. This choice
may have indicated desire for pregnancy or simply increased the
risk for pregnancy given reliance on daily pill taking. Studies that
depend on low pregnancy rates to preserve power to assess
product efficacy may consider requiring longer-acting contracep-
tion, but this is complicated by observed associations between
injectable hormonal contraception and HIV risk
[49,50,51,52,53,54]. Given that antiretroviral PrEP is one of few
prevention options for uninfected women who want to conceive
a child with an infected or high-risk partner [27,28,29,30],
including women with pregnancy or plans for pregnancy in
prevention studies may ultimately be more efficient than working
to exclude them. Second, our data suggest that women with
pregnancies were less likely to maintain high adherence to study
product. Prospective data to understand adherence in this context
are needed.
There are limitations to these data. First, our ability to explain
differences in adherence among women with pregnancies versus
those without is compromised by an inability to accurately assess
pregnancy intention or desire. Inclusion criteria for this study
included a negative answer to the question ‘‘Do you plan to
become pregnant in the next three years?’’ However, while most
women in this study were probably not planning to become
pregnant at enrollment, pregnancy planning is not static and many
pregnancies fall between the extremes of explicitly planned and
unplanned [12]. Second, studying adherence to an intervention
with unknown efficacy with blinded randomization to placebo is
challenging and makes both the measure of adherence and the
significance of the finding challenging to interpret. In addition,
adherence data for women with pregnancy events were censored
at pregnancy. Thus, women with pregnancies had a median of 7.9
Table 2. Covariates associated with adherence greater than 80% (use of 2 applicators with .80% of reported sex acts).
Odds Ratio (95%CI) p-value Adjusted Odds Ratio (95%CI) p-value
Ever pregnant (Yes vs No) 0.58 (0.46–0.73) ,0.0001 0.52 (0.41–0.66) ,0.0001
Age (per 5 year increase) 1.06 (1.03–1.10) 0.001 1.15 (1.10–1.20) ,0.0001
Education (Did not complete vs
completed high school)
1.10 (1.02–1.19) 0.01 0.86 (0.79–0.93) 0.001
Income (,145 USD vs $145 USD) 2.48 (2.10–2.94) ,0.0001 1.49 (1.21–1.82) 0.0001
Contraception (Oral vs Injectables)* 0.96 (0.86–1.06) 0.38 1.06 (0.94–1.19) 0.33
Site (Rural vs Urban) 2.57 (2.36–2.80) ,0.0001 2.65 (2.40–2.93) ,0.0001
Living with regular partner (Yes vs No) 1.24 (1.11–1.39) 0.0001 1.38 (1.2–1.57) ,0.0001
Dislike something about gel (Yes vs No) 0.68 (0.63–0.75) ,0.0001 0.87 (0.79–0.97) 0.01
*Time-updated covariate.
USD = U.S. Dollar.
95% CI =95% Confidence Interval.
N=860 for unadjusted comparisons except ‘‘dislike something about gel’’ for which N=731. N=731 for the adjusted, multivariate model.
doi:10.1371/journal.pone.0056400.t002
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pregnancies had a median of 19.2 (IQR: 14.6–23.2) months of
follow-up. We would expect this differential follow-up time to bias
our results in the opposite direction of our findings (higher
adherence among women with pregnancies) given that medication
adherence tends to decay over time [55,56]. This study was not
designed to answer questions of acceptability or efficacy of
periconception PrEP use. These preliminary findings however
provide some important considerations for future studies.
Conclusions
Antiretroviral prophylaxis may be an important component of
interventions to reduce periconception HIV transmission. In this
study, women with pregnancies were less adherent to study
product. This may reflect unintended pregnancy in the context of
imperfect contraceptive adherence and associated poor study gel
adherence. Concerns about tenofovir toxicity may have also led to
product nonuse for women who decided to conceive and wanted
to reduce fetal exposure. Further research is needed to understand
the relationship between antiretroviral prophylaxis adherence,
pregnancy intention, and concerns about fetal toxicity. In
addition, efforts to develop adherence support strategies for PrEP
and to assess feasibility of periconception PrEP use for at-risk
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